{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:46:25Z","timestamp":1792125985600,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:00:00Z","timestamp":1792108800000},"content-version":"vor","delay-in-days":87,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Anhui Provincial Translational Clinical Medicine Research Program","award":["S202424b100210207"],"award-info":[{"award-number":["S202424b100210207"]}]},{"name":"Anhui Provincial Health Project","award":["AHWJ2024BAg30015"],"award-info":[{"award-number":["AHWJ2024BAg30015"]}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2025YFE0126800"],"award-info":[{"award-number":["2025YFE0126800"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373348"],"award-info":[{"award-number":["82373348"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Hainan Boao Lecheng Real World Research and Medical Technology Innovation Joint Project","award":["ZDYF2025LCLH011"],"award-info":[{"award-number":["ZDYF2025LCLH011"]}]},{"name":"the General Surgery Clinical Key Specialty Construction Fund","award":["KGZ002"],"award-info":[{"award-number":["KGZ002"]}]},{"name":"Research and Application of Intraoperative Real-Time Navigation Technology for Pancreatic Cancer","award":["202427b10020032"],"award-info":[{"award-number":["202427b10020032"]}]},{"name":"Research and Development of Novel Precision Treatment Strategies for Hepatobiliary and Pancreatic Malignancies","award":["2023AH040254"],"award-info":[{"award-number":["2023AH040254"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biol Toxicol"],"DOI":"10.1007\/s10565-026-10219-7","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T10:13:21Z","timestamp":1784628801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanisms of synergistic action between olaparib and KPT-330 in pancreatic cancer"],"prefix":"10.1007","volume":"42","author":[{"given":"Yuntao","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yajing","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hang","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huixiang","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiqiang","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengchao","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Da","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JiaBin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoming","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"10219_CR1","doi-asserted-by":"publisher","first-page":"37355","DOI":"10.1074\/jbc.M113.494740","volume":"288","author":"HJ Abuhusain","year":"2013","unstructured":"Abuhusain HJ, et al. A metabolic shift favoring sphingosine 1-phosphate at the expense of ceramide controls glioblastoma angiogenesis. J Biol Chem. 2013;288:37355\u201364. https:\/\/doi.org\/10.1074\/jbc.M113.494740.","journal-title":"J Biol Chem"},{"key":"10219_CR2","doi-asserted-by":"publisher","first-page":"82144","DOI":"10.18632\/oncotarget.19285","volume":"8","author":"AS Azmi","year":"2017","unstructured":"Azmi AS, et al. Exportin 1 (XPO1) inhibition leads to restoration of tumor suppressor miR-145 and consequent suppression of pancreatic cancer cell proliferation and migration. Oncotarget. 2017;8:82144\u201355. https:\/\/doi.org\/10.18632\/oncotarget.19285.","journal-title":"Oncotarget"},{"key":"10219_CR3","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1158\/1078-0432.Ccr-19-1728","volume":"26","author":"AS Azmi","year":"2020","unstructured":"Azmi AS, et al. preclinical assessment with clinical validation of Selinexor with Gemcitabine and Nab-Paclitaxel for the treatment of pancreatic Ductal Adenocarcinoma. Clin Cancer Res. 2020;26:1338\u201348. https:\/\/doi.org\/10.1158\/1078-0432.Ccr-19-1728.","journal-title":"Clin Cancer Res"},{"key":"10219_CR4","doi-asserted-by":"publisher","first-page":"9305","DOI":"10.1038\/s41598-024-59994-5","volume":"14","author":"N Chakravarti","year":"2024","unstructured":"Chakravarti N, et al. XPO1 blockade with KPT-330 promotes apoptosis in cutaneous T-cell lymphoma by activating the p53\u2013p21 and p27 pathways. Sci Rep. 2024;14:9305. https:\/\/doi.org\/10.1038\/s41598-024-59994-5.","journal-title":"Sci Rep"},{"key":"10219_CR5","doi-asserted-by":"publisher","unstructured":"Corsetto PA, Zava S, Rizzo AM, Colombo I.\u00a0 The critical impact of sphingolipid metabolism in breast cancer progression and drug response. Int J Mol Sci. 2023; 24. https:\/\/doi.org\/10.3390\/ijms24032107.","DOI":"10.3390\/ijms24032107"},{"key":"10219_CR6","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1016\/j.ejso.2019.05.031","volume":"45","author":"LA Daamen","year":"2019","unstructured":"Daamen LA, et al. Postoperative surveillance of pancreatic cancer patients. Eur J Surg Oncol. 2019;45:1770\u20137. https:\/\/doi.org\/10.1016\/j.ejso.2019.05.031.","journal-title":"Eur J Surg Oncol"},{"key":"10219_CR7","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/ni.2730","volume":"14","author":"CS Garris","year":"2013","unstructured":"Garris CS, et al. Defective sphingosine 1-phosphate receptor 1 (S1P1) phosphorylation exacerbates TH17-mediated autoimmune neuroinflammation. Nat Immunol. 2013;14:1166\u201372. https:\/\/doi.org\/10.1038\/ni.2730.","journal-title":"Nat Immunol"},{"key":"10219_CR8","doi-asserted-by":"publisher","first-page":"2067","DOI":"10.1093\/annonc\/mdx180","volume":"28","author":"JW Gilbert","year":"2017","unstructured":"Gilbert JW, et al. Borderline resectable pancreatic cancer: conceptual evolution and current approach to image-based classification. Ann Oncol. 2017;28:2067\u201376. https:\/\/doi.org\/10.1093\/annonc\/mdx180.","journal-title":"Ann Oncol"},{"key":"10219_CR9","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1056\/NEJMoa1903387","volume":"381","author":"T Golan","year":"2019","unstructured":"Golan T, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317\u201327. https:\/\/doi.org\/10.1056\/NEJMoa1903387.","journal-title":"N Engl J Med"},{"key":"10219_CR10","doi-asserted-by":"publisher","first-page":"1480572","DOI":"10.3389\/fimmu.2024.1480572","volume":"15","author":"Y Gong","year":"2024","unstructured":"Gong Y, et al. Deciphering the role of NcRNAs in pancreatic cancer immune evasion and drug resistance: a new perspective for targeted therapy. Front Immunol. 2024;15:1480572. https:\/\/doi.org\/10.3389\/fimmu.2024.1480572.","journal-title":"Front Immunol"},{"key":"10219_CR11","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1186\/s13045-014-0085-1","volume":"7","author":"GL Gravina","year":"2014","unstructured":"Gravina GL, et al. Nucleo-cytoplasmic transport as a therapeutic target of cancer. J Hematol Oncol. 2014;7:85. https:\/\/doi.org\/10.1186\/s13045-014-0085-1.","journal-title":"J Hematol Oncol"},{"key":"10219_CR12","doi-asserted-by":"publisher","first-page":"2352","DOI":"10.1158\/1535-7163.Mct-21-0370","volume":"20","author":"KF Handley","year":"2021","unstructured":"Handley KF, et al. Rational combination of CRM1 inhibitor Selinexor and Olaparib shows synergy in ovarian cancer cell lines and mouse models. Mol Cancer Ther. 2021;20:2352\u201361. https:\/\/doi.org\/10.1158\/1535-7163.Mct-21-0370.","journal-title":"Mol Cancer Ther"},{"key":"10219_CR13","doi-asserted-by":"publisher","first-page":"e13237","DOI":"10.1111\/cpr.13237","volume":"55","author":"Y Huo","year":"2022","unstructured":"Huo Y, et al. Increased SPON1 promotes pancreatic ductal adenocarcinoma progression by enhancing IL-6 trans-signalling. Cell Prolif. 2022;55:e13237. https:\/\/doi.org\/10.1111\/cpr.13237.","journal-title":"Cell Prolif"},{"key":"10219_CR14","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaoncol.2021.0006","volume":"7","author":"M Javle","year":"2021","unstructured":"Javle M, et al. Olaparib monotherapy for previously treated pancreatic cancer with DNA damage repair genetic alterations other than germline BRCA variants: findings from 2 phase 2 nonrandomized clinical trials. JAMA Oncol. 2021;7:693\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2021.0006.","journal-title":"JAMA Oncol"},{"key":"10219_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.cancergen.2025.06.006","volume":"296\u2013297","author":"G Jiang","year":"2025","unstructured":"Jiang G, et al. SATB2 plays a critical role in pancreatic cancer cell proliferation, migration and T cell cytotoxicity. Cancer Genet. 2025;296\u2013297:53\u201364. https:\/\/doi.org\/10.1016\/j.cancergen.2025.06.006.","journal-title":"Cancer Genet"},{"key":"10219_CR16","doi-asserted-by":"publisher","first-page":"3929","DOI":"10.1200\/jco.21.01604","volume":"40","author":"HL Kindler","year":"2022","unstructured":"Kindler HL, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022;40:3929\u201339. https:\/\/doi.org\/10.1200\/jco.21.01604.","journal-title":"J Clin Oncol"},{"key":"10219_CR17","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1007\/s00432-022-04247-z","volume":"149","author":"JR Landes","year":"2023","unstructured":"Landes JR, et al. The efficacy of selinexor (KPT-330), an XPO1 inhibitor, on non-hematologic cancers: a comprehensive review. J Cancer Res Clin Oncol. 2023;149:2139\u201355. https:\/\/doi.org\/10.1007\/s00432-022-04247-z.","journal-title":"J Cancer Res Clin Oncol"},{"key":"10219_CR18","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1038\/nm.2250","volume":"16","author":"H Lee","year":"2010","unstructured":"Lee H, et al. STAT3-induced S1PR1 expression is crucial for persistent STAT3 activation in tumors. Nat Med. 2010;16:1421\u20138. https:\/\/doi.org\/10.1038\/nm.2250.","journal-title":"Nat Med"},{"key":"10219_CR19","doi-asserted-by":"publisher","first-page":"15534","DOI":"10.1021\/acs.jmedchem.1c01145","volume":"64","author":"S Liu","year":"2021","unstructured":"Liu S, Qiao W, Sun Q, Luo Y. Chromosome region maintenance 1 (XPO1\/CRM1) as an anticancer target and discovery of its inhibitor. J Med Chem. 2021;64:15534\u201348. https:\/\/doi.org\/10.1021\/acs.jmedchem.1c01145.","journal-title":"J Med Chem"},{"key":"10219_CR20","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1016\/j.bulcan.2019.07.002","volume":"106","author":"C Louvet","year":"2019","unstructured":"Louvet C, Samalin E, Michel P. Olaparib and pancreatic cancer: a challenging Lesson. Bull Cancer. 2019;106:715\u20136. https:\/\/doi.org\/10.1016\/j.bulcan.2019.07.002.","journal-title":"Bull Cancer"},{"key":"10219_CR21","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.18632\/oncotarget.28047","volume":"12","author":"H Marijon","year":"2021","unstructured":"Marijon H, et al. Selinexor, a selective inhibitor of nuclear export, enhances the anti-tumor activity of Olaparib in triple negative breast cancer regardless of BRCA1 mutation status. Oncotarget. 2021;12:1749\u201362. https:\/\/doi.org\/10.18632\/oncotarget.28047.","journal-title":"Oncotarget"},{"key":"10219_CR22","doi-asserted-by":"publisher","first-page":"20595","DOI":"10.1021\/acs.jmedchem.4c02169","volume":"67","author":"H Miao","year":"2024","unstructured":"Miao H, et al. Discovery of SZJK-0421: A novel potent, low toxicity, selective second generation of CRM1 inhibitor for the treatment of both hematological and solid tumors. J Med Chem. 2024;67:20595\u2013618. https:\/\/doi.org\/10.1021\/acs.jmedchem.4c02169.","journal-title":"J Med Chem"},{"key":"10219_CR23","doi-asserted-by":"publisher","unstructured":"Pai Bellare G, Saha B, Patro BS. Targeting autophagy reverses de novo resistance in homologous recombination repair proficient breast cancers to PARP inhibition. British J Cancer. 2021;124:1260\u20131274. https:\/\/doi.org\/10.1038\/s41416-020-01238-0\u00a0.","DOI":"10.1038\/s41416-020-01238-0"},{"key":"10219_CR24","doi-asserted-by":"publisher","first-page":"884377","DOI":"10.3389\/fonc.2022.884377","volume":"12","author":"Q Pan","year":"2022","unstructured":"Pan Q, Yi C, Zhang Y. Overall survival signature of 5-methylcytosine regulators related long non-coding RNA in hepatocellular carcinoma. Front Oncol. 2022;12:884377. https:\/\/doi.org\/10.3389\/fonc.2022.884377.","journal-title":"Front Oncol"},{"key":"10219_CR25","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1001\/jama.2021.13027","volume":"326","author":"W Park","year":"2021","unstructured":"Park W, Chawla A, O\u2019Reilly EM. Pancreatic Cancer: A Review. Jama. 2021;326:851\u201362. https:\/\/doi.org\/10.1001\/jama.2021.13027.","journal-title":"Jama"},{"key":"10219_CR26","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1158\/1535-7163.Mct-20-0365","volume":"20","author":"LA Parsels","year":"2021","unstructured":"Parsels LA, et al. Combinatorial efficacy of olaparib with radiation and atr inhibitor requires PARP1 protein in homologous recombination-proficient pancreatic cancer. Mol Cancer Ther. 2021;20:263\u201373. https:\/\/doi.org\/10.1158\/1535-7163.Mct-20-0365.","journal-title":"Mol Cancer Ther"},{"key":"10219_CR27","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.21037\/tcr-21-169","volume":"10","author":"Y Pu","year":"2021","unstructured":"Pu Y, et al. The clinical application of (18)F-FDG PET\/CT in pancreatic cancer: a narrative review. Transl Cancer Res. 2021;10:3560\u201375. https:\/\/doi.org\/10.21037\/tcr-21-169.","journal-title":"Transl Cancer Res"},{"key":"10219_CR28","doi-asserted-by":"publisher","unstructured":"Qui\u00f1onero F, et al. PARP1 inhibition by Olaparib reduces the lethality of pancreatic cancer cells and increases their sensitivity to Gemcitabine. Biomed Pharmacother. 2022;155:113669. https:\/\/doi.org\/10.1016\/j.biopha.2022.113669.","DOI":"10.1016\/j.biopha.2022.113669"},{"key":"10219_CR29","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1186\/1471-2350-14-122","volume":"14","author":"BJ Reardon","year":"2013","unstructured":"Reardon BJ, et al. Vitamin D-responsive SGPP2 variants associated with lung cell expression and lung function. BMC Med Genet. 2013;14:122. https:\/\/doi.org\/10.1186\/1471-2350-14-122.","journal-title":"BMC Med Genet"},{"key":"10219_CR30","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/cncr.32600","volume":"126","author":"JM Santiago-O'Farrill","year":"2020","unstructured":"Santiago-O\u2019Farrill JM, et al. Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagy-mediated drug resistance in ovarian cancer cells, xenografts, and patient-derived xenograft models. Cancer. 2020;126:894\u2013907. https:\/\/doi.org\/10.1002\/cncr.32600.","journal-title":"Cancer"},{"key":"10219_CR31","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1038\/bjc.2014.260","volume":"111","author":"H Sun","year":"2014","unstructured":"Sun H, et al. KPT-330 has antitumour activity against non-small cell lung cancer. Br J Cancer. 2014;111:281\u201391. https:\/\/doi.org\/10.1038\/bjc.2014.260.","journal-title":"Br J Cancer"},{"key":"10219_CR32","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1038\/leu.2013.115","volume":"28","author":"YT Tai","year":"2014","unstructured":"Tai YT, et al. CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications. Leukemia. 2014;28:155\u201365. https:\/\/doi.org\/10.1038\/leu.2013.115.","journal-title":"Leukemia"},{"key":"10219_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s13578-025-01350-9","volume":"15","author":"XM Tang","year":"2025","unstructured":"Tang XM, et al. TOPBP1 as a potential predictive biomarker for enhanced combinatorial efficacy of Olaparib and AZD6738 in PDAC. Cell Biosci. 2025;15:17. https:\/\/doi.org\/10.1186\/s13578-025-01350-9.","journal-title":"Cell Biosci"},{"key":"10219_CR34","doi-asserted-by":"publisher","first-page":"e1513","DOI":"10.1002\/ctm2.1513","volume":"13","author":"MH Uddin","year":"2023","unstructured":"Uddin MH, et al. Molecular analysis of XPO1 inhibitor and gemcitabine-nab-paclitaxel combination in KPC pancreatic cancer mouse model. Clin Transl Med. 2023;13:e1513. https:\/\/doi.org\/10.1002\/ctm2.1513.","journal-title":"Clin Transl Med"},{"key":"10219_CR35","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1158\/1535-7163.Mct-24-0210","volume":"24","author":"VM Valvo","year":"2025","unstructured":"Valvo VM, et al. Olaparib and radiotherapy induce type I Interferon- and CD8+ T Cell-dependent sensitization to immunotherapy in pancreatic cancer. Mol Cancer Ther. 2025;24:843\u201358. https:\/\/doi.org\/10.1158\/1535-7163.Mct-24-0210.","journal-title":"Mol Cancer Ther"},{"key":"10219_CR36","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1080\/15548627.2023.2252301","volume":"20","author":"LH Wang","year":"2024","unstructured":"Wang LH, et al. KPT330 promotes the sensitivity of glioblastoma to Olaparib by retaining SQSTM1 in the nucleus and disrupting lysosomal function. Autophagy. 2024;20:295\u2013310. https:\/\/doi.org\/10.1080\/15548627.2023.2252301.","journal-title":"Autophagy"},{"key":"10219_CR37","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1016\/j.bbagen.2016.10.006","volume":"296\u2013306","author":"YS Wu","year":"1861","unstructured":"Wu YS, et al. Paracrine IL-6 signaling mediates the effects of pancreatic stellate cells on epithelial-mesenchymal transition via Stat3\/Nrf2 pathway in pancreatic cancer cells. Biochim Biophys Acta. 1861;296\u2013306:2017. https:\/\/doi.org\/10.1016\/j.bbagen.2016.10.006.","journal-title":"Biochim Biophys Acta"},{"key":"10219_CR38","doi-asserted-by":"publisher","first-page":"106040","DOI":"10.1016\/j.phrs.2021.106040","volume":"175","author":"SQ Wu","year":"2022","unstructured":"Wu SQ, et al. FDI-6 and Olaparib synergistically inhibit the growth of pancreatic cancer by repressing BUB1, BRCA1 and CDC25A signaling pathways. Pharmacol Res. 2022;175:106040. https:\/\/doi.org\/10.1016\/j.phrs.2021.106040.","journal-title":"Pharmacol Res"},{"key":"10219_CR39","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1186\/s12943-025-02385-9","volume":"24","author":"J Zhang","year":"2025","unstructured":"Zhang J, et al. CircERC1 facilitates chemoresistance through inhibiting pyroptosis and remodeling extracellular matrix in pancreatic cancer. Mol Cancer. 2025;24:185. https:\/\/doi.org\/10.1186\/s12943-025-02385-9.","journal-title":"Mol Cancer"},{"key":"10219_CR40","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1007\/s00280-014-2495-8","volume":"74","author":"Y Zheng","year":"2014","unstructured":"Zheng Y, et al. KPT-330 inhibitor of XPO1-mediated nuclear export has anti-proliferative activity in hepatocellular carcinoma. Cancer Chemother Pharmacol. 2014;74:487\u201395. https:\/\/doi.org\/10.1007\/s00280-014-2495-8.","journal-title":"Cancer Chemother Pharmacol"},{"key":"10219_CR41","doi-asserted-by":"publisher","unstructured":"Zhou J, et al. Guidelines for the diagnosis and treatment of primary liver cancer, (2022 Edition). Liver Cancer. 2023;12:405\u2013444. https:\/\/doi.org\/10.1159\/000530495.","DOI":"10.1159\/000530495"},{"key":"10219_CR42","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12943-020-01167-9","volume":"19","author":"H Zhu","year":"2020","unstructured":"Zhu H, et al. PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications. Mol Cancer. 2020;19:49. https:\/\/doi.org\/10.1186\/s12943-020-01167-9.","journal-title":"Mol Cancer"},{"key":"10219_CR43","doi-asserted-by":"publisher","first-page":"670353","DOI":"10.3389\/fonc.2021.670353","volume":"11","author":"Y Zhu","year":"2021","unstructured":"Zhu Y, et al. NUDT21 promotes tumor growth and metastasis through modulating SGPP2 in human gastric cancer. Front Oncol. 2021;11:670353. https:\/\/doi.org\/10.3389\/fonc.2021.670353.","journal-title":"Front Oncol"}],"container-title":["Cell Biology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10565-026-10219-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-026-10219-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-026-10219-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T04:09:29Z","timestamp":1792123769000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10565-026-10219-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["10219"],"URL":"https:\/\/doi.org\/10.1007\/s10565-026-10219-7","relation":{},"ISSN":["1573-6822"],"issn-type":[{"value":"1573-6822","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"28 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This in vivo study was approved by the Animal Ethics Committee of Shanghai Jiao Tong University (No. A2025094-002) and conducted in accordance with international standards. The study involving human samples was approved by the Ethics Committee of Wannan Medical University (Approval No. 2024\u2013223). Informed consent was obtained from all participants. All bioinformatics images are sourced from the TCGA database, and ethics approval is not applicable.","order":1,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"118"}}